Mouse CLEC4F/CLECSF13 Antibody

CLEC4F/CLECSF13 in Mouse Liver.

CLEC4F/CLECSF13 was detected in perfusion fixed frozen sections of mouse liver using Goat Anti-Mouse CLEC4F/CLECSF13 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2784) at 5 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Specific staining was localized to Kupffer cells. View our protocol for Chromogenic IHC Staining of Frozen Tissue Sections.

Detection of Mouse CLEC4F/CLECSF13 by Western Blot

L-glutamine treatment does not ameliorate ischemic injury in SCD mouse liver. (A) Quantitative liver intravital (qLIM) imaging of three different fields of view of SCD mice at baseline and post-L-glutamine administration injected with TXR-dextran. Dotted circle shows loss of blood flow in SCD liver which was comparable in L-glutamine-treated SCD mouse liver. (B) Quantification of the total area (%) of liver with loss of blood flow in SCD mice at baseline and post-L-glutamine treatment. (C) Representative IF images show enhanced CLEC4F and F4/80 expression in SCD liver which was not seen after L-glutamine administration. (D) Western Blot for CLEC4F and CD45 antibodies exhibits increased expression in the liver of SCD mice compared to L-glutamine-treated SCD mouse liver. (E) qRT-PCR analysis exhibits reduced mRNA expression of markers of inflammatory cells (including F4/80, Cd45, CLEC4F, and IL1 beta) in L-glutamine-treated SCD liver compared to SCD liver at baseline. * denotes p < 0.05, NS, Not significant. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37760853), licensed under a CC-BY license. Not internally tested by R&D Systems.